AG真人官方

Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine

Peer-reviewed publication highlights ATI-1701鈥檚 robust protection against aerosolized Francisella tularensis exposure in multiple animal models

HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the 鈥淐ompany鈥� or 鈥淎ppili鈥�), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures,听today announced a new publication in the journal Vaccine, supporting the efficacy of its biodefense vaccine candidate, ATI-1701. The manuscript, titled, details studies showing robust and durable protection from lethal tularemia exposure in both rat and non-human primate models.

ATI-1701, a live attenuated strain of F. tularensis, is being developed as a first-in-class vaccine to protect against tularemia, a highly contagious and potentially fatal bacterial disease. The publication, co-authored by Dr. Carl Gelhaus, Director of Non-Clinical Research at Appili, and researchers from leading biodefense institutions in the U.S., Canada, and Sweden, highlights key findings from multiple preclinical studies.

鈥淭his publication marks a significant milestone in the development of ATI-1701 and adds to the growing body of evidence supporting its protective potential,鈥� said Dr. Carl Gelhaus. 鈥淚n both rats and cynomolgus macaques, ATI-1701 showed strong immunity against aerosolized F. tularensis SCHU S4 鈥� one of the most virulent strains and most concerning routes of exposure. Protection was dose-dependent, long-lasting, and associated with robust immune responses, including strong antigen-specific antibody titers.鈥�

Key results from the study include:

• 100% survival in rats challenged with aerosolized SCHU S4 up to one-year post-vaccination, even at challenge doses >10,000x the median lethal dose (LD₅₀).
• In cynomolgus macaques, ATI-1701 demonstrated up to 100% protection, reduced disease severity, and improved histopathological outcomes.
• Immunized animals exhibited robust antibody responses, correlating with survival and supporting the vaccine鈥檚 immunogenic potential.
  
  

This study reinforces ATI-1701鈥檚 potential as a leading candidate for tularemia prevention and supports continued development in partnership with the U.S. Department of Defense.

ATI-1701 is the Company鈥檚 first-in-class vaccine candidate for the prevention of infection with听F. tularensis. Since it is a highly infectious pathogen capable of causing severe illness, medical countermeasures for F. tularensis are a top biodefense priority for governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets, strengthening听ATI-1701鈥檚 position as a potentially valuable vaccine urgently needed on the market.听听

About ATI-1701听
ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, which causes tularemia, a Category A pathogen which can be aerosolized and is over 1,000 times more infectious than anthrax. Since it is a highly infectious pathogen capable of causing severe illness, medical counter measures for F. tularensis are a top biodefense priority for the United States and governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets.

About Appili Therapeutics听
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili鈥檚 goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit听. 听听

Forward looking statements听
This news release contains 鈥渇orward-looking statements鈥�, including with respect to further anticipated milestones and the timing thereof and the Company鈥檚 development plans with respect to ATI-1701. Wherever possible, words such as 鈥渕ay,鈥� 鈥渨ould,鈥� 鈥渃ould,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥減lan,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渆stimate,鈥� 鈥減otential for鈥� and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company鈥檚 management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk that ATI-1701 may never become an approved vaccine for the prevention or treatment of tularemia, and the other risks listed in the annual information form of the Company dated June 25, 2025, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

Media Contact:听
Jenna McNeil, Communications Manager听
Appili Therapeutics听听
E: 听

Investor Relations Contact:听
Don Cilla, President and CEO听
Appili Therapeutics听
E: 听听